2013 Annual General Meeting
Access for Participants by Webcast and Conference Call
GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer
GI Dynamics, Inc. Reports on Progress of the ENDO Trial
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE